Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma-Reference-Cited by-同舟云学术

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Published:2018-09-28 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Kondrashova Olga^ORCID, ,Topp Monique,Nesic Ksenija,Lieschke Elizabeth,Ho Gwo-Yaw,Harrell Maria I.,Zapparoli Giada V.,Hadley Alison,Holian Robert,Boehm Emma,Heong Valerie,Sanij Elaine,Pearson Richard B.^ORCID,Krais John J.,Johnson Neil,McNally Orla,Ananda Sumitra,Alsop Kathryn,Hutt Karla J.,Kaufmann Scott H.^ORCID,Lin Kevin K.,Harding Thomas C.,Traficante Nadia,deFazio Anna,McNeish Iain A.^ORCID,Bowtell David D.,Swisher Elizabeth M.,Dobrovic Alexander,Wakefield Matthew J.^ORCID,Scott Clare L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-05564-z.pdf

Reference54 articles.

1. Audeh, M. W. et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251 (2010).

2. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).

3. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).

4. Matulonis, U. A. et al. Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly (adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer 122, 1844–1852 (2016).

5. Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016).

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination Proficient Ovarian Cancer Cells;Current Cancer Drug Targets;2024-08-26

2. PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments;Current Opinion in Oncology;2024-08-23

3. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

4. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance;Molecular Cancer;2024-08-05

5. Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy;Cancer Letters;2024-08